FSD Pharma Doubles Down on Endocannabinoid-based Pain Management -- CFN Media

Seattle, Washington--(Newsfile Corp. - May 1, 2019) - CFN Media Group ("CFN Media"), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FSE: 0K9). The company has already staked out its plans to address this crisis through endocannabinoid-based treatment options. After partnering with SciCann Therapeutics, the company recently announced the planned acquisition of a specialty pharmaceutical company focused on the space.

Chronic pain is a widespread condition affecting about one-third of the American population and billions of other people around the world. Despite their widely known dangers, opioids quickly became one of the most prescribed and profitable classes of drugs in the world. The ensuing opioid crisis has made overdoses a leading cause of non-disease deaths in the United States, as well as an emerging health crisis worldwide.

Opioids vs. Cannabinoids

Chronic pain affects more than 100 million Americans at an annual cost of $600 billion, according to the Institute of Medicine. According to the National Institute of Drug Abuse, between 20 and 30 percent of chronic pain patients misuse opioid drugs and up to 12 percent go on to develop an addiction. More than 60 Americans ultimately die from opioid doses every day, making it a leading cause of non-disease death after suicide.

Cannabinoids, like opioids, are known for their analgesic and pain relieving effects. Rather than binding to opioid receptors, cannabinoids bind to CB1 and CB2 receptors to block pain signals. These parallel mechanisms of action mean that cannabinoids and opioids could be used together to combat pain. Early research suggests that cannabinoids could be especially helpful for neuropathic and centralized pain conditions, such as fibromyalgia.

FSD Pharma has taken an active approach to targeting the endocannabinoid system as a way toward reducing pain without-or with fewer-opioids. In partnership with SciCann, a Canadian-Israeli specialty pharmaceutical company, it's already helping develop and commercialize cannabinoid-based pharmaceuticals. A pilot study in Pittsburgh, PA is testing the safety and efficacy of cannabidiol (CBD) for the treatment of irritable bowel syndrome.

FSD Pharma's Acquisition

FSD Pharma more recently announced the $17.5 million acquisition of Prismic Pharmaceuticals Inc., a U.S.-based specialty pharmaceutical company developing non-addictive prescription drugs with unique safety profiles with the goal of addressing the opioid crisis, pending various closing conditions. Prismic's drug formulations are focused on the 'entourage effect' that micro-palmitoylethanolamide has on certain drugs impacting the endocannabinoid system.

"This transaction symbolizes FSD Pharma's vision of acquiring a platform company to advance research and development of FDA-approved applications of synthetic cannabinoids and other synergistic molecules," said FSD Pharma Executive Co-Chairman & CEO Dr. Raza Bokhari. "Led by Peter Moriarty, one of the founders of Shire Pharmaceuticals, Prismic's management team has built a solid foundation for a specialty pharmaceutical company."

Prismic has exclusive worldwide licensing rights (except for Italy and Spain) to a patented form of palmitoylethanolamide (PEA) that has an 'entourage effect' on certain drugs impacting the endocannabinoid system. For example, the company's lead drug candidate, PP-101, is a 600mg tablet form of micro-PEA that is used in conjunction with pregabalin (Lyrica®) for the treatment of fibromyalgia. Future drugs will focus on cannabinoids and opioids.

Looking Ahead

FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FSE: 0K9) has been increasingly positioning itself as a leader in the research and development of pain management solutions targeting the endocannabinoid system. In conjunction with its 3.8 million sq. ft. former Kraft facility, the company is uniquely positioned to become a leading producer of specialty cannabis products-including potential pharmaceutical combinations.

For more information, visit the company's website at www.fsdpharma.com.

Please follow the link to read the full article on CFN:

https://www.cannabisfn.com/fsd-pharma-doubles-down-on-endocannabinoid-based-pain-management/

About CFN Media

CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.

Learn how to become a CFN Media client company, brand or entrepreneur: http://www.cannabisfn.com/featuredcompany

Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand: https://itunes.apple.com/us/app/cannabisfn/id988009247?ls=1&mt=8

Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone: http://www.cannabisfn.com

Disclaimer

CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on http://www.cannabisfn.com (the 'Site') is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

Frank Lane
206-369-7050
Flane@cannabisfn.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/44448

info